The perinucleolar compartment: structure, function, and utility in anti-cancer drug development

ABSTRACT

The perinucleolar compartment (PNC) was initially identified as a nuclear structure enriched for the polypyrimidine tract-binding protein. Since then, the PNC has been implicated in carcinogenesis. The prevalence of this compartment is positively correlated with disease progression in various types of cancer, and its expression in primary tumors is linked to worse patient outcomes. Using the PNC as a surrogate marker for anti-cancer drug efficacy has led to the development of a clinical candidate for anti-metastasis therapies. The PNC is a multicomponent nuclear body situated at the periphery of the nucleolus. Thus far, several non-coding RNAs and RNA-binding proteins have been identified as the PNC components. Here, we summarize the current understanding of the structure and function of the PNC, as well as its recurrent links to cancer progression and metastasis.

KEYWORDS:

• Anti-cancer drug development
• non-coding RNA
• nucleolus
• PNC
• RNA binding proteins

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

Work in our laboratories has been supported by NIH [S.H.: U01CA260699, and R01 CA269967] and Biotechnology and Biological Sciences Research Council [E.V.M.; BB/M001199/1, BB/R001049/1, and BB/V006258/1].